Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys

(2009) BR Ito et al.   BRITISH JOURNAL OF PHARMACOLOGY

Hepatic insulin resistance, metabolic syndrome and cardiovascular disease

(2009) Reza Meshkani et al.   CLINICAL BIOCHEMISTRY

Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine

(2009) Hai Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements

(2009) Hai Li et al.   JOURNAL OF LIPID RESEARCH

Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels

(2009) D. Steinberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Berberine decreases PCSK9 expression in HepG2 cells

(2008) Jamie Cameron et al.   ATHEROSCLEROSIS

Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: Evidence for statin-induced hepatic insulin sensitization

(2008) Mark Naples et al.   ATHEROSCLEROSIS

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

(2008) Robert J. Schmidt et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment

(2008) G. Lambert et al.   CLINICAL CHEMISTRY

PCSK9 as a therapeutic target of dyslipidemia

(2008) Nabil G Seidah   EXPERT OPINION ON THERAPEUTIC TARGETS

Errata.PCSK9 function and physiology: Fig. 1.

(2008) Andrew S. Peterson et al.   JOURNAL OF LIPID RESEARCH

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

(2008) Aldo Grefhorst et al.   JOURNAL OF LIPID RESEARCH

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease

(2008) Guoqing Cao et al.   Endocrine Metabolic & Immune Disorders-Drug Targets